TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3843115

Group type: EXPERIMENTAL
Intervention: Instructions for control over noise
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Noise-induced stress
Number of subjects: 150
Study: 31612981

Group type: EXPERIMENTAL
Intervention: Contraceptive methods (various types including contraceptive pill, withdrawal, breast-feeding)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Age, duration of marriage, and high monthly income
Number of subjects: 400
Study: 29355894

Group type: EXPERIMENTAL
Intervention: Distribution-based methods (0.2 SD of baseline POEM scores)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Distribution-based methods (0.5 SD of baseline POEM scores)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Patient-/parent-reported anchor-based methods
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Investigator-reported anchor-based methods
Number of subjects: 300
Study: 27925082

Group type: EXPERIMENTAL
Intervention: Intervention-group (a) - health counseling, nutrition and physical activity
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Intervention-group (b) - health counseling, nutrition and physical activity
Number of subjects: 42
Study: 24823280

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Metformin-based OAD
Number of subjects: 47
Study: 23659733

Group type: EXPERIMENTAL
Intervention: Continued warfarin treatment
Number of subjects: 681

Group type: COMPARATOR
Intervention: Bridging therapy with heparin
Number of subjects: 681
Study: 20632044

Group type: EXPERIMENTAL
Intervention: Dynamic fixation transition (DFT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Circumferential single‐level fusion (SLF)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (DFT and SLF)
Number of subjects: 60
Study: 18444052

Group type: EXPERIMENTAL
Intervention: Early intervention programs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lovaas's treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other treatments
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 15882879

Group type: EXPERIMENTAL
Intervention: Famotidine (40 mg per day p.o. for 1 week pre-operatively)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 12519286

Group type: EXPERIMENTAL
Intervention: Care delivered by a clinical nurse specialist (CNS) in a rheumatology outpatient clinic (12 weeks)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Inpatient team care (2 weeks)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Day patient team care (3 weeks)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: All three groups (CNS, inpatient, day patient)
Number of subjects: 210
Study: 10658883

Group type: EXPERIMENTAL
Intervention: JOBS workshop
Number of subjects: 1801

Group type: COMPARATOR
Intervention: Baseline job-search motivation and sense of mastery
Number of subjects: 1801

Group type: COMPARATOR
Intervention: Initial low levels of job-search motivation and mastery
Number of subjects: 1801
Study: 9289463

Group type: EXPERIMENTAL
Intervention: Pregnant women in the III trimester of gestation
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Puerperium (third day after delivery)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Cord serum of newborn infants
Number of subjects: 325
Study: 1502420

Group type: EXPERIMENTAL
Intervention: Oligoallergenic diet
Number of subjects: 1339

Group type: EXPERIMENTAL
Intervention: Double-blind food challenge
Number of subjects: 1339

Group type: COMPARATOR
Intervention: Food allergy/asthma prevalence
Number of subjects: 1339

Group type: COMPARATOR
Intervention: Food antigen positivity
Number of subjects: 1339
Study: 6745850

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 115
Study: 30587949

Group type: EXPERIMENTAL
Intervention: Functional Training (FT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Strength Training (ST)
Number of subjects: 12
Study: 29599421

Group type: EXPERIMENTAL
Intervention: Virtual Patient-based training session
Number of subjects: 170

Group type: COMPARATOR
Intervention: Video-recorded standard lecture
Number of subjects: 170
Study: 27978842

Group type: EXPERIMENTAL
Intervention: Fast-track surgery (FTS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional management
Number of subjects: 0
Study: 25267738

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) continued for an additional 6 months (group A1)
Number of subjects: 347

Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH) discontinued (group A2)
Number of subjects: 347

Group type: COMPARATOR
Intervention: No LMWH (group B)
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 347
Study: 22337161

Group type: EXPERIMENTAL
Intervention: Opioid blockade (8 mg naloxone i.v.)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 19194341

Group type: EXPERIMENTAL
Intervention: Drospirenone 2 mg/estradiol 1 mg (group 1; n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Norethisterone acetate 0.5 mg/estradiol 1 mg (group 2; n = 15)
Number of subjects: 30
Study: 17458908

Group type: EXPERIMENTAL
Intervention: Screening arm (PSA screening)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm (no screening)
Number of subjects: 0
Study: 16014067

Group type: EXPERIMENTAL
Intervention: Low dose dalteparin (bolus of 40 IU/kg body weight)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No additional anticoagulation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low dose dalteparin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard oral anticoagulation (phenprocoumon)
Number of subjects: 10
Study: 11894705

Group type: EXPERIMENTAL
Intervention: Intensive physical therapy (3.6 hours/week)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (1.9 hours/week)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 88
Study: 10618886

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) at a dose of 0.7 IU/kg per week for 12 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-GH treated (control)
Number of subjects: 20
Study: 7605770

Group type: COMPARATOR
Intervention: 12 mg hyperbaric 0.75% bupivacaine in 8.25% dextrose
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 15 mg hyperbaric 0.75% bupivacaine in 8.25% dextrose
Number of subjects: 28
Study: 1664824

Group type: EXPERIMENTAL
Intervention: Temafloxacin
Number of subjects: 3355

Group type: COMPARATOR
Intervention: Quinolone comparators
Number of subjects: 3355

Group type: COMPARATOR
Intervention: Non-quinolone comparators
Number of subjects: 3355

Group type: EXPERIMENTAL
Intervention: Temafloxacin (high dose)
Number of subjects: 3355
Study: 6184567

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 43

Group type: COMPARATOR
Intervention: Diuretic therapy
Number of subjects: 43

Group type: COMPARATOR
Intervention: Beta-blockers
Number of subjects: 43
Study: 31625954

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (20 U for forehead lines, 20 U for glabellar lines, with/without 24 U in crow's feet)
Number of subjects: 176

Group type: COMPARATOR
Intervention: OnabotulinumtoxinA
Number of subjects: 176
Study: 29924167

Group type: EXPERIMENTAL
Intervention: High-fidelity clinical simulation
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional laboratory practice class
Number of subjects: 52
Study: 26517954

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Relaxation Therapy (RT)
Number of subjects: 189
Study: 25032141

Group type: EXPERIMENTAL
Intervention: Oral midazolam 0.5 mg/kg
Number of subjects: 84

Group type: COMPARATOR
Intervention: No sedative medication (Control)
Number of subjects: 84
Study: 22146238

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 20636634

Group type: EXPERIMENTAL
Intervention: Valnoctamide (600 mg/day increased to 1200 mg after four days)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 18198637

Group type: EXPERIMENTAL
Intervention: Intravenous injection of propofol (Pro I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acupuncture at Shenting (DU24) and Yintang (EX‐HN3) with needle retention
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Shenting (DU24) and Yintang (EX‐HN3)
Number of subjects: 60

Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 60

Group type: COMPARATOR
Intervention: BIS measurements
Number of subjects: 60
Study: 15204824

Group type: EXPERIMENTAL
Intervention: Relative plus absolute risk presentation
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Absolute risk only presentation
Number of subjects: 353

Group type: COMPARATOR
Intervention: No risk presentation (control group)
Number of subjects: 353
Study: 12068251

Group type: EXPERIMENTAL
Intervention: 0.8 g/kg ethanol
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 0.4 g/kg ethanol
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 9871427

Group type: EXPERIMENTAL
Intervention: Moxonidine treatment after 3, 5, and 11 weeks
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo during run-in phase
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Moxonidine treatment after 8 weeks
Number of subjects: 141
Study: 8563674

Group type: EXPERIMENTAL
Intervention: Walking intervention (n = 16)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (n = 11)
Number of subjects: 27
Study: 2694343

Group type: EXPERIMENTAL
Intervention: Furazolidone (7.5 mg/kg/day for 5 days)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (8 mg/40 mg/kg/day for 5 days)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control (no antimicrobials)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Furazolidone
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control
Number of subjects: 125
Study: 38261

Group type: EXPERIMENTAL
Intervention: Clobazam (40 mg daily, increased to 80 mg daily by day 3 if well tolerated)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 31676280

Group type: EXPERIMENTAL
Intervention: Chemoradiation therapy (CMT)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Radical cystectomy (RC)
Number of subjects: 5
Study: 30937600

Group type: EXPERIMENTAL
Intervention: Exercise (6 weeks of moderate-intensity walking and resistance exercise)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Chemotherapy alone (control group)
Number of subjects: 293
Study: 28272220

Group type: EXPERIMENTAL
Intervention: Doxazosin + Duloxetine (4mg + 30mg, increased to 60mg after 1 week)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Sertraline + Doxazosin (4mg + 50mg)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Doxazosin (4mg)
Number of subjects: 150
Study: 26299324

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg bolus followed by 1.5 mg/kg/h continuous infusion)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 30
Study: 24060577

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy with detectable circulating tumor cells (CTCs)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Neoadjuvant therapy without detectable circulating tumor cells (CTCs)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Patients with detectable HER2-positive CTCs prior to surgery
Number of subjects: 51
Study: 21119518

Group type: EXPERIMENTAL
Intervention: Low-flow inhalational anaesthesia (1 l min(‐1) O2 + 0.5 l min(‐1) N2O + desflurane)
Number of subjects: 50

Group type: COMPARATOR
Intervention: High-flow inhalational anaesthesia (3 l min(‐1) O2 + 1.5 l min(‐1) N2O + desflurane)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 19702485

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 17341377

Group type: EXPERIMENTAL
Intervention: Glass fiber and zircon post (Fibio) and composite resin (Durafil) core
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nickel‐chromium (NiCr) cast post and core
Number of subjects: 12
Study: 15007518

Group type: EXPERIMENTAL
Intervention: Counselling
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Cognitive group therapy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Waiting list (Control)
Number of subjects: 63
Study: 11471630

Group type: EXPERIMENTAL
Intervention: Forensic evaluation model
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Forensic evaluation procedure
Number of subjects: 147
Study: 18069178

Group type: EXPERIMENTAL
Intervention: 2% w/w minocycline gel (Dentomycin)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo gel (control)
Number of subjects: 22
Study: 7967807

Group type: EXPERIMENTAL
Intervention: Biofeedback gait training (BFB group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional gait training without biofeedback (reference group)
Number of subjects: 0
Study: 3068174

Group type: EXPERIMENTAL
Intervention: Catheter change over guidewire (group I)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Replacement by a new contralateral venipuncture (group II)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group (group III) requiring only one catheterization
Number of subjects: 146
Study: 31901439

Group type: EXPERIMENTAL
Intervention: Non-dieting intervention
Number of subjects: 94

Group type: COMPARATOR
Intervention: Brochure control
Number of subjects: 94
Study: 29998359

Group type: EXPERIMENTAL
Intervention: Neuromuscular blocker (NM) group
Number of subjects: 112

Group type: COMPARATOR
Intervention: Non-neuromuscular blocker (non-NM) group
Number of subjects: 112
Study: 27368430

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (TH) to 33.5 °C
Number of subjects: 92

Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (TH)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Inotropic support
Number of subjects: 92
Study: 26556688

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study: 22984174

Group type: EXPERIMENTAL
Intervention: 2010 ACR/EULAR classification criteria
Number of subjects: 303

Group type: COMPARATOR
Intervention: 1987 classification criteria
Number of subjects: 303
Study: 20592389

Group type: EXPERIMENTAL
Intervention: FEC (500/100/500)-docetaxel (100)
Number of subjects: 2669

Group type: COMPARATOR
Intervention: FEC (500/100/500)-docetaxel/gemcitabine (75/2000)
Number of subjects: 2669
Study: 18463891

Group type: EXPERIMENTAL
Intervention: Sodium chloride drink with 1 mmol/l sodium concentration
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sodium chloride drink with 31 mmol/l sodium concentration
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sodium chloride drink with 40 mmol/l sodium concentration
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sodium chloride drink with 50 mmol/l sodium concentration
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sodium-free drink (control)
Number of subjects: 8
Study: 17138196

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.3 mg) and postoperative PCA intravenous morphine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (PCA alone)
Number of subjects: 52
Study: 14627850

Group type: EXPERIMENTAL
Intervention: Coralline hydroxyapatite implants
Number of subjects: 38

Group type: COMPARATOR
Intervention: High density porous polyethylene (Medpore) implants
Number of subjects: 38
Study: 10749346

Group type: EXPERIMENTAL
Intervention: CARTO nonfluoroscopic three-dimensional mapping system
Number of subjects: 79

Group type: COMPARATOR
Intervention: Conventional mapping technique
Number of subjects: 79
Study: 8873540

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (flumazenil vehicle)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 12
Study: 1567097

Group type: EXPERIMENTAL
Intervention: Guideline-based consultation in addition to usual care (N=46)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Usual care alone (N=55)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Guideline-based consultation (N=46)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Usual care (N=55)
Number of subjects: 101
Study: 3929402

Group type: EXPERIMENTAL
Intervention: Cefoxitin (Mefoxin; MSD)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: MPT (metronidazole, penicillin and tobramycin)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Colorectal surgery
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Biliary surgery
Number of subjects: 97
Study: 30916654

Group type: EXPERIMENTAL
Intervention: Health system websites
Number of subjects: 140
Study: 29669039

Group type: COMPARATOR
Intervention: Sanitation
Number of subjects: 6694

Group type: COMPARATOR
Intervention: Handwashing
Number of subjects: 6694

Group type: COMPARATOR
Intervention: WSH (Water, Sanitation, Handwashing)
Number of subjects: 6694

Group type: COMPARATOR
Intervention: Nutrition plus WSH (N+WSH)
Number of subjects: 6694

Group type: COMPARATOR
Intervention: Chlorinated drinking water
Number of subjects: 6694

Group type: COMPARATOR
Intervention: Nutrition interventions
Number of subjects: 6694

Group type: COMPARATOR
Intervention: Combined WSH interventions
Number of subjects: 6694
Study: 27098822

Group type: EXPERIMENTAL
Intervention: Colistin plus meropenem combination therapy
Number of subjects: 360

Group type: COMPARATOR
Intervention: Colistin monotherapy
Number of subjects: 360
Study: 23479192

Group type: EXPERIMENTAL
Intervention: HIV prevention intervention
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: History of abuse
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Partner communication frequency scores
Number of subjects: 254
Study: 22682898

Group type: EXPERIMENTAL
Intervention: Denufosol (60 mg via inhalation three times daily)
Number of subjects: 466

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Denufosol
Number of subjects: 466
Study: 20679620

Group type: EXPERIMENTAL
Intervention: Vinblastine (6 mg/m²) during each chemotherapy course followed by weekly vinblastine for a total of 1 year
Number of subjects: 217

Group type: COMPARATOR
Intervention: No vinblastine
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Vinblastine
Number of subjects: 217
Study: 17880718

Group type: EXPERIMENTAL
Intervention: Local corticosteroid injections
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care (analgesics as needed)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cost effectiveness of corticosteroid injection therapy
Number of subjects: 150
Study: 16141015

Group type: EXPERIMENTAL
Intervention: Heliox-driven albuterol therapy
Number of subjects: 160

Group type: COMPARATOR
Intervention: O(2) group
Number of subjects: 160
Study: 12126069

Group type: EXPERIMENTAL
Intervention: Onion juice
Number of subjects: 38

Group type: COMPARATOR
Intervention: Tap water (control)
Number of subjects: 38
Study: 10080332

Group type: EXPERIMENTAL
Intervention: Sclerokeratoplasty
Number of subjects: 20

Group type: COMPARATOR
Intervention: Therapeutic penetrating keratoplasty
Number of subjects: 20
Study: 7745800

Group type: EXPERIMENTAL
Intervention: 5 ml of 4% lidocaine HCl
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2 mg of nicardipine HCl + 5 ml of distilled water
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2 mg of verapamil HCl + 5 ml of distilled water
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2 mg of diltiazem HCl + 5 ml of distilled water
Number of subjects: 10
Study: 2134114

Group type: EXPERIMENTAL
Intervention: Buspirone (initial dose 15 mg, mean final dose 22.2 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Oxazepam (initial dose 45 mg, mean final dose 55.8 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Buspirone and Oxazepam (both groups)
Number of subjects: 26
Study: 6776571

Group type: EXPERIMENTAL
Intervention: Smoking (S) condition
Number of subjects: 28

Group type: COMPARATOR
Intervention: Non-Smoking (NS) condition
Number of subjects: 28
Study: 31900166

Group type: EXPERIMENTAL
Intervention: Caffeine supplementation (6 mg/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 29890542

Group type: EXPERIMENTAL
Intervention: Leucine administration (25g) with glucose infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (250ml water with glucose infusion)
Number of subjects: 10
Study: 28220582

Group type: EXPERIMENTAL
Intervention: Kinesio Taping bandage applied on vertebral regions corresponding to uterine dermatomes (T10 to L1 and S2 to S4)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bandage application away from uterine dermatomes (T1 to T4)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Kinesio Taping bandage
Number of subjects: 60
Study: 27259300

Group type: EXPERIMENTAL
Intervention: Combined treatment of Tirofiban and Fondaparinux
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fondaparinux
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tirofiban
Number of subjects: 0
Study: 23790741

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT) for 8 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 23

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 23
Study: 21464426

Group type: EXPERIMENTAL
Intervention: Interferon β‐1b 250 μg
Number of subjects: 2244

Group type: EXPERIMENTAL
Intervention: Interferon β‐1b 500 μg
Number of subjects: 2244

Group type: COMPARATOR
Intervention: Glatiramer acetate (GA)
Number of subjects: 2244
Study: 20128320

Group type: EXPERIMENTAL
Intervention: Total Advanced Clean dentifrice (0.3% triclosan, 2% copolymer, dual phase silica)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Colgate Total Advanced Clean (control)
Number of subjects: 144